Further clinical studies should evaluate the mutations of APP and its mediated pathways or molecules in both PDR and AD patients, and this could be implemented in PDR screening programs to reduce the risk of developing progressive neurodegenerative diseases like AD. Here, APP is linked to Alzheimer disease.